Kymera Therapeutics Inc (KYMR NASDAQ) stock market data APIs
$30.9258
-1.45(-4.7%)
as of May 8, 2025
Kymera Therapeutics Inc Financial Data Overview
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Prev. Close
30.9258
Open
29.4713
High
31.0383
Low
28.4722
52 wk Range
19.445-53.27
Market Cap
2 187 M
Shares Outstanding
65 117 K
Revenue
47 072 K
Beta
2.189
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kymera Therapeutics Inc data using free add-ons & libraries
Get Kymera Therapeutics Inc Fundamental Data
Kymera Therapeutics Inc Fundamental data includes:
- Net Revenue: 47 072 K
- EBITDA: -250 736 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-30
- EPS/Forecast: -0.73
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kymera Therapeutics Inc News
New
Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicine...
Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference
Kymera Therapeutics, Inc. WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small m...
Why Kymera Therapeutics Stock Crushed it This Week
According to data compiled by S&P Global Market Intelligence, Kymera Therapeutics(NASDAQ: KYMR) notched an almost 23% share price gain across this week. That made it a standout in the ever-volatile bi...
Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025
Kymera Therapeutics, Inc. Watertown, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
